GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01432353
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01423539
A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01423318
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
- Conditions
- Ovarian Cancer
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01422265
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Drug: FOLFOX regimenDrug: Placebo
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT01418222
- Locations
- 🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇺🇸Toledo Comm. Onc. Program, Toledo, Ohio, United States
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Drug: Corticosteroids
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01414205
- Locations
- 🇺🇸
Arizona Oncology, Tucson, Arizona, United States
🇺🇸Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States
🇺🇸Arizona Clinical Research Ctr, Tucson, Arizona, United States
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01414855
- Locations
- 🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Onc Hem Assoc of Central IL, Peoria, Illinois, United States
🇺🇸Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01399684
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01397578
- Locations
- 🇪🇸
Hospital Mutua De Terrasa, Barcelona, Spain
🇺🇸NNS Clinical Research LLC, Tucson, Arizona, United States
🇺🇸Pacific Neuroscience Med Grp, Oxnard, California, United States
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 661
- Registration Number
- NCT01375842
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Uni of Chicago, Chicago, Illinois, United States
🇺🇸New York Oncology Hematology, P.C., Albany, New York, United States